A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice-Reference-Cited by-同舟云学术

A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice

Published:2016-08-23 Issue:2 Volume:42 Page:524-539
ISSN:0893-133X
Container-title:Neuropsychopharmacology
language:en
Short-container-title:Neuropsychopharmacol

Author:

Cuadrado-Tejedor Mar,Garcia-Barroso Carolina,Sánchez-Arias Juan A,Rabal Obdulia,Pérez-González Marta,Mederos Sara,Ugarte Ana,Franco Rafael,Segura Victor,Perea Gertrudis,Oyarzabal Julen,Garcia-Osta Ana

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Pharmacology

Link

http://www.nature.com/articles/npp2016163.pdf

Reference69 articles.

1. Bayer KU, Schulman H (2001). Regulation of signal transduction by protein targeting: the case for CaMKII. Biochem Biophys Res Commun 289: 917–923.

2. Benito E, Urbanke H, Ramachandran B, Barth J, Halder R, Awasthi A et al (2015). HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models. J Clin Invest 125: 3572–3584.

3. Bliss TV, Collingridge GL (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31–39.

4. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T et al (1996). Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005–1013.

5. Chiu CT, Wang Z, Hunsberger JG, Chuang DM (2013). Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 65: 105–142.

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design of Multi-Target drugs of HDACs and other Anti-Alzheimer related Targets: Current strategies and future prospects in Alzheimer’s diseases therapy;Bioorganic Chemistry;2024-10

2. Role of histone deacetylases and their inhibitors in neurological diseases;Pharmacological Research;2024-09

3. An overview of conventional and investigational phosphodiesterase 5 inhibitors for treating erectile dysfunction and other conditions;Expert Opinion on Investigational Drugs;2024-08-11

4. Restoring the epigenome in Alzheimer's disease: advancing HDAC inhibitors as therapeutic agents;Drug Discovery Today;2024-07

5. The broken Alzheimer’s disease genome;Cell Genomics;2024-05